Game-based App for Type 1 Diabetes
(DVx-T1D Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify whether participants need to stop taking their current medications. However, since the study involves a mobile app and standard care, it is likely that participants will continue their current insulin regimen.
What data supports the effectiveness of the treatment DVx-T1D™ app, Digital Vaccine for Type 1 Diabetes?
Research suggests that digital games can help people with diabetes manage their condition by motivating them to change their behavior and lifestyle. While more studies are needed, gamification (using game-like elements) has shown potential benefits in diabetes management, which may support the effectiveness of the DVx-T1D™ app.12345
How is the DVx-T1D™ app treatment different from other treatments for type 1 diabetes?
The DVx-T1D™ app is unique because it uses gamification (turning tasks into games) to help people with type 1 diabetes manage their condition, making it more engaging and motivating compared to traditional methods. This approach is designed to improve self-management by encouraging regular monitoring and lifestyle changes through interactive and fun activities.34567
What is the purpose of this trial?
The goal of this study is to evaluate the impact of a mobile app video game called Digital Vaccine for Type 1 Diabetes (DVx-T1D)™, proposed as a low-risk, non-invasive, digital therapeutic candidate for behavior change in children 6 to 12 years of age with Type 1 Diabetes (T1D).The investigators hypothesize that adoption of DVx-T1D™ by T1D patients will positively influence healthy dietary and physical activity behaviors by providing nutrition and lifestyle education through a playful, Artificial Intelligence (AI)-based, cartoon-style medium of mobile gaming, and result in improvements in their T1D control. The investigators propose to conduct a longitudinal randomized controlled trial (RCT) over a 3-month period with a study population of 80 T1D participants (40 each in two arms of the trial) of 6-12 years old. The investigators will quantify the impact of the mobile game app plus standard care vs. standard care (with no exposure to the app) on T1D control (assessed by glycosylated hemoglobin or HbA1c measured during clinic visits and continuous glucose monitoring (CGM) parameters measured at home), physical activity levels and food choices of children (measured using food logs and surveys). Game telemetry, food logs, clinical, anthropometric, demographic, and survey data will be collected to obtain adequately powered, theory-driven evidence of the value of game-based approaches delivered via mobile apps.
Eligibility Criteria
This trial is for children aged 6 to 12 with Type 1 Diabetes. They should be willing to use the DVx-T1D™ app alongside their standard diabetes care and participate in activities like food logging and surveys. The study excludes details on who can't join, but typically those with other health issues or unable to follow the trial procedures would be excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Evaluation
Participants are evaluated at baseline for anthropometrics, clinical, and laboratory data
Treatment
Participants receive either standard care or standard care plus the DVx-T1D game for 3 months
Follow-up
Participants are monitored for changes in HbA1c, glucose levels, and lifestyle behaviors
Treatment Details
Interventions
- DVx-T1D™ app
Find a Clinic Near You
Who Is Running the Clinical Trial?
Carnegie Mellon University
Lead Sponsor
University of Pittsburgh
Collaborator